Importantly, the associations between KRAS activation and the expression of PD-L1 should always be interpreted in the context of the respective tumor origin, as studies have revealed that KRAS mutations in CRC can result in inverted effects on PD-L1 expression levels compared to lung or pancreatic cancer (184, 185). This evidence concerns the gene CD274 and familial pancreatic carcinoma.